All patients
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), pembrolizumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-598, 2020 1.08 [0.85; 1.37]
0.79 [0.68 ; 0.92 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020 5 61% 3,564 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
0.79 [0.68 ; 0.92 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 4 67% 2,996 moderate not evaluable PFS (extension)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
0.82 [0.64 ; 1.06 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 4 89% 2,996 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-598, 2020 1.06 [0.86; 1.30]
0.87 [0.71 ; 1.07 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020 5 83% 3,564 moderate serious objective responses (ORR)detailed results KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-598, 2020 1.00 [0.72; 1.39]
1.24 [1.01 ; 1.54 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020 5 53% 3,564 moderate serious objective responses (ORR) (extension)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
1.26 [1.02 ; 1.57 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019 4 45% 2,996 moderate not evaluable STRAE (any grade)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
1.05 [0.60 ; 1.82 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable STRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
0.97 [0.55 ; 1.72 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable TRAE (any grade)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
0.22 [0.14 ; 0.34 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 44% 1,555 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
0.30 [0.24 ; 0.38 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
0.81 [0.39 ; 1.66 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
0.88 [0.62 ; 1.24 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
1.05 [0.71 ; 1.55 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
3.88 [0.17 ; 86.15 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
0.07 [0.00 ; 1.21 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
0.06 [0.03 ; 0.12 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.02 ; 48.81 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
0.29 [0.08 ; 1.05 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.49 [0.02 ; 14.58 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
3.90 [0.65 ; 23.43 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.06 ; 15.56 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
0.44 [0.16 ; 1.24 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
1.95 [0.07 ; 58.69 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
3.57 [0.98 ; 13.00 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.97 [0.02 ; 49.41 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
0.37 [0.13 ; 1.04 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
13.68 [0.77 ; 241.54 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.44 [0.11 ; 18.83 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
3.62 [0.38 ; 34.25 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.44 [0.11 ; 18.83 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
1.94 [0.35 ; 10.63 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
1.75 [0.58 ; 5.26 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
0.24 [0.04 ; 1.55 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.05 [0.00 ; 0.82 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.97 [0.02 ; 49.41 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
0.10 [0.01 ; 0.82 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.18 ; 21.52 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
0.02 [0.00 ; 0.10 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
1.44 [0.11 ; 18.87 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.10 [0.01 ; 1.76 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.08 [0.00 ; 1.43 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
9.73 [1.92 ; 49.42 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 16% 1,555 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
3.88 [0.17 ; 86.15 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.97 [0.02 ; 49.41 ] KEYNOTE-024 (PDL1>50%), 2016 1 0% 304 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
5.82 [0.29 ; 116.52 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
11.23 [2.11 ; 59.83 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.41 [0.04 ; 4.70 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
0.08 [0.02 ; 0.43 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.06 ; 15.56 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
0.52 [0.07 ; 4.14 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,555 moderate not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.14 [0.41; 3.20]
1.14 [0.41 ; 3.20 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.01 [0.36; 11.05]
2.01 [0.36 ; 11.05 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.25 [0.03; 2.22]
0.25 [0.03 ; 2.22 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
0.50 [0.04 ; 5.51 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.14; 7.12]
1.00 [0.14 ; 7.12 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
6.03 [0.30 ; 120.98 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 10.29 [1.31; 80.96]
10.29 [1.31 ; 80.96 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.87 [0.31; 2.43]
0.87 [0.31 ; 2.43 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.51 [0.42; 5.39]
1.51 [0.42 ; 5.39 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.00 [0.06; 16.01]
1.00 [0.06 ; 16.01 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.52 [0.48; 13.09]
2.52 [0.48 ; 13.09 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.28 [0.69; 7.50]
2.28 [0.69 ; 7.50 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.01 [0.18; 89.26]
4.01 [0.18 ; 89.26 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-598, 2020 1.36 [0.72; 2.56]
1.36 [0.72 ; 2.56 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-598, 2020 2.21 [0.83; 5.91]
2.21 [0.83 ; 5.91 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-598, 2020 0.50 [0.04; 5.51]
0.50 [0.04 ; 5.51 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-598, 2020 6.03 [0.30; 120.98]
6.03 [0.30 ; 120.98 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-598, 2020 16.38 [0.94; 286.59]
16.38 [0.94 ; 286.59 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-598, 2020 4.03 [0.45; 36.27]
4.03 [0.45 ; 36.27 ] KEYNOTE-598, 2020 1 0% 563 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 01:33 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 359,575,577,576,869
